Figure 1From: Pharmacokinetics, Safety and Inducible Cytokine Responses during a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (Givinostat)Platelet counts in healthy volunteers receiving 7-day oral doses of ITF2357 or placebo. Mean platelet counts in ITF2357-treated group receiving 50, 100 and 200 mg ITF2357 each day, respectively, are shown.Back to article page